Materials and Methods

Study Population
We studied consecutive adult patients ≥ 18 years of age with PAH, first seen at the Mayo Clinic Rochester, between December 2003 and March 2006, who were naive to PAH-specific therapy. Individuals were included if they fulfilled the contemporary diagnostic criteria for PAH (ie, group 1 PH with mean pulmonary artery pressure [mPAP] ≥ 25 mm Hg at rest occurring in the setting of increases in precapillary pulmonary resistance). Patients with congenital systemic-to-pulmonary shunts were excluded. Two patients were excluded because of hemodynamically significant pericardial effusions and 12 because echocardiographic images were inadequate for the assessment of RV strain by the speckle-tracking method. The remaining 80 patients agreed to the use of their data for research, and the study was approved by the institutional review board (Committee Expedited Review B-IRB 06-005447 and 09-007824).
The estimated glomerular filtration rate was derived by the Modified Diet in Renal Disease equation. [32] Clinical status at 6 months was assessed in 73 of the 74 surviving patients based on a clinical evaluation by a member of the PH clinic staff (71 in person, two by telephone, at 5.9 ± 0.9 months). Evidence of right-sided heart failure at follow-up was defined as the presence of more than trivial edema and/or ascites in the setting of neck vein distension. Survival was censored at 4 years with vital status available over this period through clinical follow-up in all subjects.
Echocardiography
Echocardiographic images were reviewed by a study echocardiologist (A. S., J.-F. H., or G. C. K.) unaware of the clinical, laboratory, and hemodynamic information. Two-dimensional (2-D) and Doppler echocardiography were performed according to standard American Society of Echocardiography guidelines. [33] The lateral tricuspid annulus systolic excursion distance was measured from 2-D images. Measures of longitudinal excursion by M-mode, which allows superior frame rates and likely more accurate measurements, were not performed routinely. RA pressure estimation was based on interrogation of the inferior vena cava diameter and distensibility and pulse-wave Doppler interrogation of the hepatic vein flow, and was scored as 5, 10, 15, or 20 mm Hg. The mPAP was calculated as the mean trans-tricuspid valve gradient + estimated right atrial pressure (RAP), [34] and the diastolic pressure was derived from the equation diastolic PA pressure = (2 × mPAP) -systolic PA pressure. The RV index of myocardial performance (Tei index) was calculated as described. [13] PA capacitance was calculated as the Doppler-derived stroke volume/PA pulse pressure. [35] The pulmonary vascular resistance index (PVRI) was calculated as the mean PA pulse pressure divided by the cardiac index. [36] 
RV Strain and Strain Rate
A three-beat, 2-D, digital clip of apical four-chamber view of the RV (average frame rate 39.4 ± 11 frames/s) was transferred to a Syngo Vector Velocity Imaging workstation (Siemens Medical Solutions; Mountain View, California) for analysis of systolic strain, time-to-peak systolic strain, and systolic and diastolic strain rate. The RV endocardium was traced with 10 to 15 points starting and ending at the tricuspid valve annulus. Negative strain values indicate tissue shortening/contraction. Positive strain values indicate tissue lengthening. A global RV value was calculated by averaging the value of six segments. Mean values of the septal and lateral free walls were also calculated. The correlation coefficient in a subgroup (n = 10) blinded assessment of intraobserver variability was 0.91 for RV free wall strain and 0.82 for RV free wall systolic strain rate (blinded repeat review performed 8 weeks after initial review) and for interobserver variability was 0.89 for RV free wall strain and 0.63 for RV free wall systolic strain rate.
Invasive Hemodynamics
Acute vasodilator testing was performed in the majority (n = 65) with a positive vasodilator response defined as a fall in mPAP of ≥ 10 mm Hg to a level of ≤ 40 mm Hg without a concomitant fall in cardiac output. [37] The decision as to whether to perform acute vasodilator testing was made by the individual managing PH physician. The reasons not to perform vasodilator testing included active/progressive disease despite calcium channel blocker use or severe World Health Organization (WHO) functional class (FC) IV disease, often in the setting of connective tissue disease.
Data Analysis
Statistical analyses were performed using JMP, version 8.0 (SAS Institute Inc; Cary, North Carolina). Continuous variables were presented as mean ± SD or median with interquartile range and were tested between groups using analysis of variance. Categoric variables were presented as number and percentage, with comparisons by Pearson χ 2 analysis.
The distribution of RV free wall strain was separated into thirds, with the lowest tertile being defined as those with an RV free wall strain below -12.5%. The relationship of RV free wall strain to clinical variables and outcomes of interest was assessed either as a continuous or dichotomous variable as outlined. The dichotomous value of above or below -12.5% also corresponded to the optimal cut point on a receiver operating characteristic curve used to test the ability of RV free wall strain to predict 1-year survival. Cox proportional hazards regression models were used to identify correlates of mortality. Results are presented as hazard ratios with 95% CIs. Models were developed with stepwise techniques and with consideration of variables that were clinically relevant. Variables included were RV free wall strain, age, sex, WHO FC, PAH cause, 6-min walk distance, and echocardiographic (RV fractional area change, estimated RAP, Tei index, lateral tricuspid valve annular displacement, and PA capacitance) and RHC (mPAP, mean RAP, cardiac, RV stroke volume, and PVRI) variables. Follow-up of patients is presented based on the Kaplan-Meier productlimit method and compared between groups using the log-rank test. For all analyses, P < .05 was considered to be significant.
Results
The baseline characteristics of the study population are summarized in Table 1 and echocardiographic variables in Table 2 . The majority of patients were WHO FC III (63%) or IV (9%), with elevated RAP and PVRI, with significant depression in cardiac index, mixed venous oxygen saturation, and RV stroke volume index. Patients had, on average, moderate-severe/severe enlargement of the RA and RV. Conventional measures of RV function were significantly reduced (lateral tricuspid annular systolic displacement, fractional area change, and RV [Tei] index of myocardial performance). Twenty patients received parenteral, and seven received inhaled prostacyclin analog therapy; 39 received an oral endothelin receptor antagonist and 28 a phosphodiesterase-5 inhibitor. Seven patients initially received calcium channel blockers alone. Thirty-one were anticoagulated with warfarin to a goal international normalized ratio of 2 to 2.5. Six patients died within 6 months. Of the remaining 73 patients evaluated at 6 months, the average WHO FC was 2.6 ± 0.7 (from 2.8 ± 0.7 at baseline). Forty-three patients reported a similar clinical state, 24 were feeling better, and seven were feeling worse than at baseline. At 6 months, 47 patients were taking diuretic therapy for the management of right-sided heart failure. Of these, 21 had clinical evidence of edema/ascites despite diuretic therapy. The remaining 26 patients had no evidence of right-sided heart failure and were not taking diuretic therapy. Overall survival rates were 82% (95% CI, 71-88) at 1 year and 59% (95% CI, 47-69) at 4 years.
Longitudinal Strain and Strain Rate of RV
Longitudinal RV strain and systolic and early diastolic strain rate were depressed significantly (Figs 1, 2, Table  3 ). The average RV free wall strain was -15 ± 5% (normal values more negative than -25%). [31] Of all the parameters analyzed, an RV free wall strain of worse (less negative) than -12.5% (lowest tertile) was associated with a greater severity of disease, higher levels of B-type natriuretic peptide, higher RA pressure (Fig 3) , and marked depression in RV systolic function as measured by echocardiography (Fig 3) or RHC (Fig  4) . Furthermore, patients with an RV free wall strain worse than -12.5% were more likely to have smaller LV dimensions (40 ± 5 vs 44 ± 6 mm, P < .01), larger RV dimensions (40 ± 7 vs 37 ± 6 mm, P < .05), greater RV mid-diastolic dimension/LV end-diastolic dimension ratios (1.04 ± 0.3 vs 0.90 ± 0.2, P < .01), moderate to severe or severe tricuspid valve regurgitation (44% vs 28%, P < .05), and a more abnormal RV index of myocardial performance values (Tei index, 0.75 ± 0.26 vs 0.61 ± 0.9; P < .01). Data are presented as mean ± SD. See Table 2 legend for expansion of the abbreviation.
Mean PAP, mm Hg. C, O 2 sat sampled in the main pulmonary artery. D, PVRI for body surface area PVRI). E, RV SV indexed for body surface area. *P < .05. O 2 sat = mixed venous oxygen saturation; PAP = pulmonary artery pressure; PVRI = pulmonary vascular resistance index; RAP = right atrial pressure; SV = stroke volume. See Figure 1 legend for expansion of other abbreviations.
Although RV strain data were not available to physicians to influence choice of PAH therapy, those with an RV free wall strain less negative than -12.5%, compared with those with better levels, were less likely to be initially treated with calcium channel blockers alone (0/28 [0%] vs 7/52 [13%], P < .05) and more likely to be treated initially with parenteral prostacyclin analog therapy or an early (within 3 months) combination of an endothelin receptor antagonist, phosphodiesterase-5 inhibitor, and/or an inhaled prostacyclin analog (14/28
[50%] vs 14/52 [27%], P < .05). Despite these differences in early treatment, in those patients alive at 6 months, more abnormal RV free wall strain values were associated with a greater degree of disease progression, with 24% of those with an RV free wall strain > -12.5% having clinical deterioration (Fig 5A) . Average WHO FC was also higher at 6 months in those with worse RV free wall strain (3.0 ± 0.7 vs 2.4 ± 0.7, P = .001). Average WHO FC was slightly lower at 6 months in those with a mild to moderate reduction in RV strain (-0.2 ± 0.5, P < .01) but was unchanged in those with severe strain reduction (0.04 ± 0.6, P = .7).
Patients with an RV free wall strain worse than -12.5% had a higher requirement of loop diuretics and/or a greater degree of lower extremity edema (Fig 5B) at 6 months, reflecting a greater clinical degree of rightsided heart failure.
Figure 5
Association of tertiles of RV free wall systolic strain. A, With proportion of clinical deterioration at 6-month follow-up (*P < .01). B, With subsequent right-sided heart failure at 6 months as demonstrated by proportion requiring loop diuretics at 6 months and proportion with edema despite diuretics (*P < .01). C, With death over 4 years (P < .005). See Figure 1 legend for expansion of abbreviations.
As illustrated in Figure 5C , RV free wall average strain also predicted 1-, 2-, 3-, and 4-year mortality. The 1-, 2-, 3-, and 4-year survival estimates were 61% (95% CI, 42-77), 57% (95% CI, 38-74), 49% (95% CI, 34-67), and 38% (95% CI, 22-57) for those with RV free wall strain less negative than -12.5%; 89% (95% CI, 75-96), 78% (95% CI, 62-89), 67% (95% CI, 51-80), and 66% (95% CI, 49-80) for those with an RV free wall strain between -12.5% and -20%; and 100%, 100%, 93% (95% CI, 65-100) and 83% (95% CI, 50-96) for those with an RV free wall strain < -20%, P < .005. The unadjusted risk of death within the first year with an RV free wall strain > -12.5% was 6.2 (95% CI, 2.1-22.3; P < .001). When assessed as a continuous variable, the unadjusted risk of death within 1 year increased 3.3-fold (95% CI, 1.8-6.8) for every 5% decline in RV free wall strain (Table 4) . Similar to strain, worsening degrees of RV free wall systolic strain rate were also associated with a greater degree of disease progression at 6 months (Fig 6A) , a higher requirement of loop diuretics, and/or a greater degree of lower extremity edema (Fig 5B) . RV free wall systolic strain rate also predicted survival with the lowest tertile of RV free wall systolic strain rate (> -0.7 s -1 ) predicting a particularly poor survival (Fig 6) . However, more modest degrees of impairment in systolic strain rate appeared to discriminate less well than RV strain (Fig 6C) . The time to peak of the RV peak systolic strain was modestly related to survival, and RV free wall diastolic strain rate was not associated with survival (Table 4) . Data are presented as hazard ratio (lower and upper 95% CIs). HR = hazard ratio; FAC = right ventricular fractional area change by echocardiography, per 5%; FC = functional class; RAP = right atrial pressure measured at right-sided heart catheterization, per 5 mm Hg. See Table 1 for expansion of other abbreviations.
Figure 6
Association of tertiles of RV free wall systolic strain rate. A, With proportion of clinical deterioration at 6-month follow-up (*P < .01). B, With subsequent right-sided heart failure at 6 months (*P < .01). C, With death over 4 years (P < .005). See Figure 1 legend for expansion of abbreviations.
Multivariate models demonstrated that both RV free wall strain and systolic strain rate remained highly predictive of mortality, even when adjusted for age, sex, WHO FC, and PAH cause (Table 4) . Although including echocardiographic and catheterization parameters of RV systolic function led to unavoidable colinearity problems in multivariate analysis, RV free wall strain remained predictive of worse outcome regardless of which echocardiographic or catheterization parameter was included in the model (Table 4) and was the strongest predictor of death of all the measures of RV systolic function tested. The concordance index for a model predicting 2-year survival including age, sex, 6-min walk distance, WHO FC, and fractional area change increased from 0.75 to 0.84 with the addition of RV free wall strain.
Discussion
RV function is an important determinant of outcome in PAH. The assessment of RV function is challenging, however, because of its geometry and the plethora of suggested invasive and noninvasive techniques. Speckle-tracking strain echocardiography has emerged as an easily obtained and angle-independent noninvasive technique for assessing global and regional RV function. Here, the RV longitudinal systolic strain and strain rate were significantly decreased in patients with PAH. An RV free wall strain less negative than -12.5% in patients with PAH identified a cohort of patients with marked RV dysfunction and a marked predisposition to subsequent right-sided heart failure, clinical deterioration, and a high risk of death. The prognostic significance of RV free wall strain persisted after adjusting for basic demographics, FC, cause of PAH, and any alternate parameter of RV systolic function (by echocardiography or RHC).
Although an elevation in PA pressure defines the presence of PH, the degree of RV enlargement, RV contractile dysfunction, and functional parameters that tend to indicate or correlate with impaired contractile dysfunction, such as RA hypertension, pericardial effusion, or severity of tricuspid valve regurgitation, are major determinants of clinical status and mortality. [1] , [38] , [39] , [40] , [41] , [42] To date, a number of echocardiographic and catheter-derived parameters of RV systolic function, some of which appear to have independent prognostic value over clinical data, have been individually linked with outcomes in patients with PAH. [13] , [18] , [35] , [39] , [40] , [42] Cardiac magnetic resonance-derived measures of RV enlargement have also been associated with outcome. [43] The RV has a complex geometry, with muscle fibers that predominantly run in a longitudinal fashion. Unlike in the LV, the majority of contractility in the RV occurs in the longitudinal plane with the base of the RV moving toward the apex in systole. [15] , [16] , [44] Here, the amount of RV free wall longitudinal deformation (strain) and the rate of this deformation (strain rate) had excellent correlation with conventional clinical, echocardiographic, and catheter-derived measures of RV remodeling. As an angle-independent sensitive measure of global and regional myocardial contractility, strain has the advantage of distinguishing true contractility of the free wall rather than translational motion, a potential concern with singular M-mode or 2-Dderived measures of longitudinal contraction. [19] , [45] Data of strain-based analysis of RV contractility to date have largely focused on the correlation of strain/strain rate with pulmonary artery hemodynamics and/or disease severity and not necessarily in PH cohorts restricted to PAH. [28] , [29] , [30] , [31] To our knowledge, this is the first report on the ability of RV strain/strain rate to correlate not just with clinical, echocardiographic, and catheter-derived measures of RV remodeling and dysfunction, but also with future signs of right-sided heart failure, as well as with survival, in a well-defined cohort with PAH.
We purposely included patients with causes of PAH other than idiopathic and familial PAH. Although they shared similar pathophysiology and it is generally recommended that they be treated in a similar fashion, it is recognized that patients with PAH in the setting of connective tissue disease have a higher mortality. [12] Here, RV strain and strain rate predicted outcomes in these PAH patient populations regardless of cause, underscoring the fact that although the rate of death may be different in these groups, the mechanism of progressive RV dysfunction underlying mortality appears to be similarly assessed by this technique. By design, we did not include patients whose PAH was caused by a congenital systemic-to-pulmonary shunt. Therefore, our data may not be extrapolated to this cohort. Because of chronic volume overload, the rate and extent of RV remodeling in this cohort may be different, and whether RV strain and strain rate predicts outcome is less well understood. The tests here were all performed with one software system. Potentially, there may be variations between absolute values measured with different venders' systems. Doppler-based strain assessment is a potential option for patients in whom images are not satisfactory for speckle-based strain, although it is more dependent on angle and frame rate and is generally felt to be inferior to specklebased methods. This modality was not tested here. Finally, almost three-quarters of the patients had FC III/IV symptoms at the time of assessment. Although relatively typical for patients diagnosed with PAH, [46] our ability to comment on the value of RV strain/strain rate in the assessment of milder/earlier stages of disease is limited. Plausibly, RV myocardial deformation may be a sensitive marker of early RV dysfunction, as has been suggested recently in patients with connective tissue disease [47] , [48] and as is recognized in a number of LV cardiomyopathies. [49] , [50] 
Conclusions
In conclusion, noninvasive assessment of RV longitudinal systolic function by strain and strain rate independently predicts future right-sided heart failure, clinical deterioration, and mortality in patients with PAH. Speckle-tracking-based strain has the advantage of being widely available, objective, cost effective, and safe.
Emerging ultrasound technologies such as speckle-strain may play an important role in predicting prognosis, monitoring the efficacy of specific therapeutic interventions, and detecting preclinical stages of disease in PAH.
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